Morse Asset Management Inc Makes New $97,000 Investment in Emergent BioSolutions Inc. (NYSE:EBS)

Morse Asset Management Inc purchased a new position in Emergent BioSolutions Inc. (NYSE:EBS) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 14,200 shares of the biopharmaceutical company’s stock, valued at approximately $97,000.

A number of other institutional investors have also recently made changes to their positions in EBS. Charles Schwab Investment Management Inc. lifted its holdings in Emergent BioSolutions by 84.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,873,984 shares of the biopharmaceutical company’s stock valued at $6,898,000 after buying an additional 1,312,934 shares in the last quarter. American Century Companies Inc. raised its stake in shares of Emergent BioSolutions by 240.9% during the second quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock valued at $6,015,000 after acquiring an additional 623,201 shares in the last quarter. Vanguard Group Inc. grew its stake in Emergent BioSolutions by 14.7% in the first quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock worth $8,631,000 after purchasing an additional 436,911 shares in the last quarter. Federated Hermes Inc. grew its position in shares of Emergent BioSolutions by 1,314.0% during the 2nd quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock worth $1,864,000 after buying an additional 253,960 shares in the last quarter. Finally, Cetera Advisors LLC bought a new stake in Emergent BioSolutions during the first quarter valued at about $428,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Trading Down 7.5 %

Shares of Emergent BioSolutions stock opened at $6.06 on Tuesday. The company has a current ratio of 1.06, a quick ratio of 0.54 and a debt-to-equity ratio of 1.16. The firm’s 50-day moving average price is $9.34 and its 200 day moving average price is $6.23. The firm has a market capitalization of $317.56 million, a PE ratio of -0.55 and a beta of 1.60. Emergent BioSolutions Inc. has a twelve month low of $1.42 and a twelve month high of $15.10.

Emergent BioSolutions (NYSE:EBS) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($1.35). The business had revenue of $254.70 million for the quarter, compared to analyst estimates of $199.47 million. Emergent BioSolutions had a negative return on equity of 34.38% and a negative net margin of 53.26%. During the same period last year, the business earned ($1.06) EPS. On average, sell-side analysts predict that Emergent BioSolutions Inc. will post -1.98 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on EBS shares. Rodman & Renshaw reaffirmed a “buy” rating and issued a $16.00 price target on shares of Emergent BioSolutions in a report on Friday, September 13th. Benchmark reissued a “buy” rating and issued a $8.00 price target on shares of Emergent BioSolutions in a research note on Friday, August 16th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.